Pacira BioSciences, Inc. (PCRX)

From the record

Pacira BioSciences, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Pacira BioSciences, Inc.'s 10 filed years say what it did: revenue went from $270 million in fiscal 2016 to $726 million in fiscal 2025, up 11.6% a year; it rose in 9 of 9 years; it never fell from a peak; net income was positive in 5 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Pacira BioSciences, Inc.'s diluted share count shrank about 0.7% a year, and dividends and buybacks returned about 35% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 17 sales (16 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-11-03 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Pacira BioSciences, Inc. earned about 1 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 46 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 45 cents per dollar of assets, and net share issuance: its share count shrank 3.6% over the year (the filed statements).

From the record

Pacira BioSciences, Inc.'s standing among 315 graded names in its industry family: revenue of $726 million in fiscal 2025 ranks in the top 15% by size; a net margin of 1% ranks in the top 23%; revenue growth of 2.9% a year over the last 3 filed years ranks in the bottom 43% (its annual reports).

From the record

Pacira BioSciences, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Lee, Frank D. (Chief Executive Officer, as filed), filing under that title since 2024-01-04, 2.9 years (bottom 31% of its family); the 16 officers and directors filing in the last fifteen months have been on the record a median of 3.1 years (bottom 16%); 11 officer or director changes were reported on Form 8-K since 2023-11-13, against the 16 people in charge now (bottom 27%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Pacira BioSciences, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $159 million against debt of $372 million leaves -16.9% of its assets as net cash, bottom 8% of its family; cash from operations less capital spending is 18.8% of revenue (top 14%); a gross margin of 79.4% (top 35%); research spending of 16.1% of revenue (bottom 21%) (its annual report).

From the record

Pacira BioSciences, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 2.9% a year over the last three filed years against 11.6% over all 10, slowing (bottom 38% of its family); the newest year grew 3.6% (bottom 43%); research spending grew 11.4% a year (top 37%); capital spending grew -20.1% a year (bottom 44%) (its annual reports). Pacira BioSciences, Inc. reported 5 product lines in fiscal 2025: EXPAREL at $575 million (79%), ZILRETTA at $117 million (16%), Iovera at $24 million (3%), and 2 more; 2 of 5 grew against the year before (its annual report).

From the record

Pacira BioSciences, Inc.'s newest year against its own record: revenue of $726 million in fiscal 2025 came in 1.1% above the $719 million its prior three years' pace pointed to (top 42% of its family); net income of $7 million against a prior three-year average of $14 million (top 10%); a net margin of 1% against -1.9% before (bottom 40%) (its annual reports).